Toxicological Evaluation of Electronic Nicotine Delivery Products

Dr. Peitsch is Chief Scientific Officer and VP of Research and Development at Philip Morris International. He has extensive experience in tobacco harm reduction, smoking-related diseases, systems biology, toxicology, bioinformatics, chemoinformatics, high-performance computing, and knowledge management. An innovation-focused results-driven biomedical research leader, Dr. Peitsch has many years of experience managing large multi-cultural teams across several countries. He holds several patents related to proteomics, genomics, and computer science and has published over 200 book chapters, technical reports, and articles in top ranking scientific journals (cited over 22000 times). He has done pioneering work in the area of molecular modeling, cell biology, computational text analytics, and systems biology/toxicology and is a founder of several initiatives, including two start-up companies, the Swiss Institute of Bioinformatics, and the [BC]2 conference (http://www.bc2.ch). He is Chairman of the Executive Board of the Swiss Institute of Bioinformatics and an active scientific advisor to several academic and commercial entities. He has also served on the Swiss National Research Council. Dr. Peitsch is a Computerworld Honors Laureate and a recipient of several awards including the New England Business and Technology Award and the United Devices Grid Visionary Award. He holds a BSc in life sciences, MSc in physical chemistry, and PhD in biochemistry. He is also Professor of Bioinformatics at the University of Basel. Dr. Hoeng is Director of Systems Biology at Phillip Morris International and program leader. She has a profound understanding of inhalation toxicology and computational modeling of smoking-related diseases, lung cancer, COPD, and CVD. Dr. Hoeng holds a BSc in biology, MSc in bioinformatics, PhD in protein crystallography, and an executive MBA.

• 1. Tobacco Harm Reduction2. Electronic nicotine delivery devices (ENDS)3. The scientific basis for the assessment of ENDS4. Quantification of HPHC in ENDS aerosols5. Aerosol physics and dynamics6. Advanced analytical chemistry methods to characterize ENDS aerosols7. Other species of toxicological concern8. Impact of ENDS on indoor air quality9. A systems-based approach to toxicity testing10. Translational aspects of toxicity testing11. Dosimetry and human-relevant exposure12. Aerosol generation, exposure, and collection13. Toxicological assessment in vitro14. Toxicological assessment in vivo15. Assessment of in vivo models of disease16. Flavors and their toxicological assessment17. A clinical strategy for ENDS testing18. The disease risk reduction potential of ENDS19. Residual risk associated to nicotine20. Conclusion